SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary
August 13, 2025
Earnings Call Speaker Segments
Jackie Cossmon
executiveThanks, Tina. Hello, everyone, and I appreciate you being on the call for SeaStar Medical's Second Quarter 2025 Financial Results Conference Call this afternoon. This is Jackie Cossmon, representing Wheelhouse Life Science Advisors. With me today from SeaStar Medical are Eric Schlorff, our Chief Executive Officer, David Green, our Chief Financial Officer, Dr. Kevin Chung, our Chief Medical Officer, and Tim Varacek, Senior Vice President of Commercial and Business Operations. I want to remind everyone listening that management's remarks on this call will contain forward-looking statements as defined under federal securities laws. Such forward-looking statements carry risks and uncertainties, and those could make actual results differ materially from any results we anticipate. To see a list and description of those risks and uncertainties, please look at SeaStar Medical's filings with the Securities and Exchange Commission. Also, the remarks on this conference call include information that is accurate only as of the date of the live broadcast, August 13, 2025. SeaStar Medical has no obligation to revise or update any statements to reflect events or circumstances, except as the law requires. I'll now hand the call over to Eric. Eric.
Eric Schlorff
executiveThanks, Jackie. Thanks, Jackie. And I appreciate everyone being with us today. From the start of the second quarter onward, we've achieved significant strides across multiple areas. A total of 125 patients have been enrolled by us, with 12 of them in July, in the NEUTRALIZE-AKI trial; we've reported three new QUELIMMUNE customers hailing from top-rated U.S.-based children's hospitals; we announced positive survival results from the initial 20 pediatric patients treated in a commercial setting with QUELIMMUNE from the SAVE Surveillance Registry; and we raised additional capital to strengthen our balance sheet. Regarding the launch of our QUELIMMUNE product, our prediction was that sales would be lumpy during the first year, and that has proven accurate for the first half of the year. Net revenue in the first quarter surged fourfold compared with the fourth quarter, and a 15% rise in net revenue was seen by us in the second quarter. On the whole, we saw an increase of nearly 370% in revenue during the first six months of 2025 versus the first six months of launch. Because of this, we are pleased with how the QUELIMMUNE launch is progressing and intend to keep concentrating our efforts on adoption by new customers, which could lead to an upward trend in sequential quarter sales. Now, allow me to share a few words regarding the SAVE Surveillance Registry. We are particularly pleased with the early data coming from the registry, which keeps showing life-saving benefits from the QUELIMMUNE therapy. Confirming the 75% survival data is decisive from our perspective and clearly demonstrates that the QUELIMMUNE therapy is helping patients in the real-world setting. As Tim will explain, these early results are already being shared by us with existing and potential customers, with the hope of expanding the use of QUELIMMUNE in these critically ill pediatric patients with acute kidney injury or AKI. Before handing the call to Tim, I want to emphasize one final point; that is, we feel great reward upon hearing that QUELIMMUNE has helped another critically ill pediatric patient who, in many cases, had little hope of survival; with each of these cases, we recognize that we may be able to do this again and again with adult patients who suffer the same destructive hyperinflammation that shuts down organs and takes lives. The numerous stories we have heard about the use of QUELIMMUNE are why we, at SeaStar Medical, are so eager to bring the SCD therapy to a much broader market than we serve today. We believe we are well on our way; we look forward to reporting our upcoming milestone in progress during our NEUTRALIZE-AKI pivotal trial. With that as an overview, I will turn the call over to Tim to discuss our commercial achievements and market opportunities.
Tim Varacek
executiveAppreciate it, Eric, and I want to thank everybody for being on the SeaStar Medical call with us today. I'm happy to share that we have achieved solid movement on our number one objective, which is getting new sites to adopt QUELIMMUNE. Since the second quarter got underway, we have brought on three additional customers, and enthusiasm for the QUELIMMUNE therapy among the customers we already have remains robust. In particular, Texas Children's Hospital coming into the QUELIMMUNE family shows the confidence people have in the clinical results that are achievable and the strong conviction surrounding this product. It's worth noting that the top pediatric hospitals nationwide are bringing QUELIMMUNE therapy on board. Sequential growth of 15% was recorded for QUELIMMUNE net revenue in the second quarter. As Eric mentioned, we continue to expect sales to be uneven until additional pediatric hospitals come online and we develop a deeper grasp of how patient presentation patterns unfold at those hospitals. We've already begun sharing the recent early data from the SAVE Surveillance Registry with our pipeline of customers. These findings, along with the broader registry data we're hoping to present later this year at a major pediatric nephrology meeting, will deliver thorough real-world evidence that further backs the use of the QUELIMMUNE therapy. Now shifting to what could be our next product offering, SCD therapy for adult patients with AKI requiring CRRT: we've kicked off pre-commercialization work to prepare for a possible adult SCD launch, provided clinical trial results come back positive and the FDA gives its approval; we project the total U.S. market opportunity to be roughly 50x the pediatric population's size, which works out to about 200,000 patients each year, who confront organ failure and possible death without any FDA-approved treatment options other than the existing standard of care, meaning CRRT and antibiotics. At the revenue per patient we currently project, that amounts to a total addressable market exceeding $4 billion yearly in the U.S; even with only modest market penetration, we could generate substantial revenue for SeaStar Medical. For this near-term potential market, we're also projecting a more favorable adoption timeline than QUELIMMUNE in pediatrics, factoring in things like greater clinical need given the population's size, the possible absence of post-market registry obligations, and our capacity to build on pediatric customer experience with QUELIMMUNE. Beyond the adult AKI indication, the FDA has granted us breakthrough device designation for five additional indications. We think the U.S. market for our adult indications by itself encompasses hundreds of thousands of patients who presently lack approved therapies for conditions in which destructive hyperinflammation produces critical care problems, organ failure, and death. That's the reason we're so enthusiastic about what lies ahead for SeaStar Medical and the SCD therapy; with that, I'll hand the presentation to our Chief Medical Officer, Dr. Kevin Chung. Kevin.
Kevin Chung
executiveThanks, Tim, and I appreciate everyone being here today. I'm happy to share that our NEUTRALIZE-AKI pivotal trial is showing consistent momentum. As of right now, 125 patients out of a goal of 200 have been enrolled. That represents 31 more participants since Q2 began, which shows real headway even though census levels were low across the board over the summer. For anyone new to what we're doing, NEUTRALIZE-AKI is a randomized controlled trial testing whether as many as 10 treatments of 24 hours each using our SCD therapy can boost 90-day survival or renal recovery among AKI patients who need CRRT, versus CRRT by itself. The primary endpoint combines mortality or dialysis dependence at 90 days, and the study is powered for 200 patients. May also brought an important milestone. With the 100th patient enrolled, our pre-specified interim analysis was triggered, and by early August, that 100th participant had completed the 90-day follow-up. Our Data Safety Monitoring Board, or DSMB, is carrying out this analysis independently, reviewing pooled data to evaluate outcomes across the treatment and control arms. What they recommend will shape the trial's next phase. We anticipate the DSMB's recommendation arriving in Q3 2025. Among the possibilities: proceeding to 200 patients as originally planned, recalculating the total number of patients required, halting early due to overwhelming efficacy, or stopping for futility. Even though we could take any of those paths, what we're currently assuming is that things will continue according to plan, with all 200 patients getting enrolled. In order to safeguard both the science and the regulatory side, the public will hear only what the DSMB recommends — the underlying outcomes data won't be shared. Turning to how quickly enrollment is going, we can tell everyone that our sites are extremely driven and they're screening patients daily. Once someone eligible turns up, our sites are able to obtain consent and enroll a large portion of them. As a matter of fact, more than 80% of those who qualify consent and get randomized into our trial. That reflects how badly site investigators want this, along with the incredibly professional research teams who handle family members with sensitivity during the darkest moments our patients face. We want to stress again that our focus is enrolling the right kind of patient. Our protocol has strict criteria to rule out those who might lack any modifiable disease — that is, patients unlikely to benefit from any intervention. Carefully selecting the right patient matters for showing therapeutic effects and for sidestepping the pitfalls that have hurt so many earlier AKI and sepsis trials. One such enrichment criterion involves C-reactive protein, or CRP, at a level of 3.5 mg/dL. Anyone whose CRP is not above 3.5 mg/dL is excluded. Why? Because this marker of inflammation is extremely sensitive; patients whose CRP is not greater than 3.5 mg/dL lack meaningful inflammation and probably won't gain anything from our therapeutic device. So that's why we're screening these patients out. In earlier trials for interventional sepsis or AKI that targeted inflammation, lots of these kinds of patients got enrolled, and the trials failed because of it. Even so, to get our enrollment rate as high as possible, we've added certain key sites on a selective basis; we've also closed sites that weren't performing, which lets us optimize efficiency across the study and keep costs down. We're still not finished adding sites. By the close of Q3, our goal is to bring on at least three to four additional sites chosen strategically. Finally, across several locations that have already gone live, our efforts are focused on expanding screening to additional ICUs within those same hospitals. That should accelerate how quickly we bring patients into the study, and we can do it without incurring any additional start-up expenses. Based on the way projections look at this moment, we believe there remains a strong possibility that we complete enrollment prior to the close of this year. After enrollment concludes and we account for final data loss, our team will act swiftly to evaluate the findings and present them to the worldwide medical community. Assuming the primary endpoint is achieved, we intend to file our pre-market approval, or PMA, submission with the FDA. The FDA's breakthrough device status for adults with AKI who need CRRT should pave the way for a faster review process. I'm also happy to report that we recently shared, in a July press release, the top line results from our SAVE Surveillance Registry. Among the initial 20 severely ill pediatric patients who received QUELIMMUNE through this real-world registry, 28-day survival came in at 75%, and there were zero device-related safety issues. These kids were incredibly sick, and for most of them the therapy was a final option. Despite that, 75% survived the acute, life-threatening period, which offers strong evidence that mortality could be cut by over half compared with historical benchmarks. From my vantage point as an ICU doctor, seeing results that beat what we anticipated makes us even more certain that QUELIMMUNE is providing these critically ill kids with a real opportunity to survive. Findings this positive have injected a huge surge of energy into our SeaStar clinical team, both for the pediatric launch and the adult study. What we are all aiming for has not shifted at any point; it is our constant guide: to speed up pediatric clinical adoption, to rescue the greatest possible number of ailing children, and eventually to achieve the same for adults. NEUTRALIZE-AKI is what we are concentrating on right now, yet our wider plan continues to be broadening SCD therapy's application across various hyperinflammatory conditions. We think this platform could transform how care is delivered, not just for AKI but for both children and grown-ups. Now, I'll pass things along to David Green, our CFO.
David Green
executiveThanks, Kevin, and I appreciate everyone being here today. I'm going to walk through the financial results for our second quarter, then wrap up with a few expectations for what's left of 2025. To start with a bit of housekeeping: our Form 10-Q is going to be submitted to the SEC within the coming 24 hours. It's available on seastarmedical.com as well as sec.gov. Before getting into the second quarter numbers, I want to mention that from the start of Q2 onward, we've hit several important milestones as a company. We've put ourselves in position to keep building on the first three quarters of commercial revenue for QUELIMMUNE and continued moving the adult NEUTRALIZE-AKI pivotal trial ahead. Our priorities have seen solid progress, and as we noted in today's press release, I'd like to call out three accomplishments. To begin with, we've moved the NEUTRALIZE-AKI pivotal trial forward in adults, enrolling 31 additional patients as of today, which brings total enrollment to 125 out of the 200-patient target needed to finish the trial. Next, QUELIMMUNE adoption has grown, with three new customers added since Q2 began. And third, we brought in $12.4 million of fresh equity capital via a public offering plus two registered direct offerings, all priced at the market. With that covered, let's look at our second quarter 2025 financial results. We posted our highest quarterly revenue ever, with a 15% sequential quarter increase driven by sales of QUELIMMUNE therapy. Second quarter 2025 revenue came in at $338,000, versus roughly $293,000 during the first quarter of 2025, and $0 in last year's comparable second quarter. Revenue for the year to date totaled $631,000. We credit the Q2 revenue growth to current customers increasing how much they use QUELIMMUNE, along with new hospital customers coming on board and buying QUELIMMUNE therapy. Turning to gross profit, the Q2 financials show a gross profit margin of about 92%. As I mentioned last quarter, Q2 was a transitional period in which we started recognizing COGS. That aligns with GAAP and stems from sales of QUELIMMUNE units previously recorded as research and development expense. Once we build and subsequently sell new inventory as a commercial business, we'll book additional costs of goods sold that match sales out of inventory. Operating expenses fell to roughly $2.1 million in the second quarter of 2025, down from $4.7 million in Q2 of 2024. That decrease mostly came from lower personnel costs and clinical trial expenses, since the bulk of our new clinical trial site activations happened during 2024 and those come with upfront initiation costs; we also saw reduced spending on preclinical research, audit fees, and professional services. Lastly, our net loss for the second quarter of 2025 shrank to $2 million, compared with a loss of $3.2 million in Q2 of 2024. We closed the quarter holding $6.3 million in cash and carrying no debt. One more thing worth mentioning — after June 30, so it doesn't show up on the Q2 balance sheet, we brought in $8.6 million via a pair of registered direct offerings plus the exercise of a warrant. Going ahead, our resources will be aimed at three main priorities: first, getting the NEUTRALIZE-AKI pivotal trial in adults finished; second, getting ready to submit a PMA once that adult AKI pivotal trial wraps up; and third, bringing in new customers for QUELIMMUNE. To close, as we push these strategic goals forward, we anticipate that momentum will keep building as we deliver our life-saving therapy to additional patients and clinicians, and as a growing number of investors recognize the sizable market opportunity taking shape for our SCD therapy. With that, I'll pass things back to Eric. Eric?
Eric Schlorff
executiveAppreciate that, Dave. What we set out to do on today's call about our Q2 financials was give everyone a rundown of where we stand, plus a clear sense of why we see the opportunities ahead for SeaStar Medical as substantial. It excites us that we can deliver a therapy that saves lives to critically ill people who, as things stand, have nothing else to turn to for settling the cytokine storm that an overactive immune system sets off. Several milestones lie ahead of us, and once enrollment wraps up in the NEUTRALIZE-AKI pivotal trial, we're eager to share the findings. Should those data hold up, our plan is to submit a PMA in 2026. Assuming approval, we think there's a major chance to claim a considerable share of the adult AKI market. Bottom line, we feel we keep building real value for our investors and stakeholders, and we'll aim to shut what looks to us like a big distance between where our market cap sits now and the future we envision for this company. So with that, I'll hand it to the operator to take questions. Operator?
Jackie Cossmon
executiveThanks, Tina. I appreciate everyone being here for SeaStar Medical's conference call on our financial results for the second quarter. Should you have any inquiries, reach out to us at ir@seastarmed.com, or check out our site to view the newest updates, offerings, pipeline developments, and details about the company. Thanks to you all, and farewell.
Operator
operatorThanks once more for being with us. That brings today’s presentation to a close. You’re welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.